These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 4058753)

  • 1. Parkinson's disease and hypertension: chronic bromocriptine treatment.
    Montastruc JL; Chamontin B; Rascol A
    Neurology; 1985 Nov; 35(11):1644-7. PubMed ID: 4058753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [How do we explain the antihypertensive effect of bromocriptine? Clinical and experimental contribution].
    Chamontin B; Montastruc JL; Rascol A
    Arch Mal Coeur Vaiss; 1984 Oct; 77(11):1181-5. PubMed ID: 6151826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bromocriptine in Parkinson's disease: a study of cardiovascular effects.
    Quinn N; Illas A; Lhermitte F; Agid Y
    J Neurol Neurosurg Psychiatry; 1981 May; 44(5):426-9. PubMed ID: 7264689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of orthostatic hypotension in Parkinson's disease.
    Senard JM; Raï S; Lapeyre-Mestre M; Brefel C; Rascol O; Rascol A; Montastruc JL
    J Neurol Neurosurg Psychiatry; 1997 Nov; 63(5):584-9. PubMed ID: 9408097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Long-term results of treatment of Parkinson's disease with bromocriptine and domperidone (author's transl)].
    Agid Y; Quinn N; Lhermitte F
    Rev Neurol (Paris); 1981; 137(1):49-51. PubMed ID: 7232966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease.
    Soykan I; Sarosiek I; Shifflett J; Wooten GF; McCallum RW
    Mov Disord; 1997 Nov; 12(6):952-7. PubMed ID: 9399220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine agonists in the treatment of Parkinson's disease.
    Rinne UK
    Adv Neurol; 1983; 37():141-50. PubMed ID: 6305175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pleuropulmonary fibrosis due to bromocriptine treatment for Parkinson's disease.
    Todman DH; Oliver WA; Edwards RL
    Clin Exp Neurol; 1990; 27():79-82. PubMed ID: 2129961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of parkinson's disease with bromocriptine.
    Lieberman A; Kupersmith M; Estey E; Goldstein M
    N Engl J Med; 1976 Dec; 295(25):1400-4. PubMed ID: 989885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjunctive therapy with bromocriptine in Parkinson's disease.
    Temlett JA; Ming A; Saling M; Fritz VU; Blumenfeld A; Bilchik TR; Becker AL; Fourie PB; Reef HE
    S Afr Med J; 1990 Dec; 78(11):680-5. PubMed ID: 2251616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bromocriptine as the 1st treatment of Parkinson's disease. Long term results].
    Rascol A; Montastruc JL; Guiraud-Chaumeil B; Clanet M
    Rev Neurol (Paris); 1982; 138(5):401-8. PubMed ID: 7146724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
    Grimes JD; Delgado MR
    Clin Neuropharmacol; 1985; 8(1):73-7. PubMed ID: 3978651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertension with orthostatic hypotension: interest of verapamil.
    Chamontin BF; Montastruc JL; Salvador MJ
    J Cardiovasc Pharmacol; 1987; 10 Suppl 10():S114-6. PubMed ID: 2455108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose bromocriptine in the early phases of Parkinson's disease.
    Tolosa E; Blesa R; Bayes A; Forcadell F
    Clin Neuropharmacol; 1987 Apr; 10(2):168-74. PubMed ID: 3332610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between supine hypertension and orthostatic hypotension in autonomic failure.
    Goldstein DS; Pechnik S; Holmes C; Eldadah B; Sharabi Y
    Hypertension; 2003 Aug; 42(2):136-42. PubMed ID: 12835329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets.
    Espay AJ; LeWitt PA; Hauser RA; Merola A; Masellis M; Lang AE
    Lancet Neurol; 2016 Aug; 15(9):954-966. PubMed ID: 27478953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment with high-dosage bromocriptine in advanced Parkinson's disease.
    Jansen EN; Meerwaldt JD
    Adv Neurol; 1987; 45():539-42. PubMed ID: 3103396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retroperitoneal fibrosis in two patients with Parkinson's disease treated with bromocriptine.
    Kains JP; Hardy JC; Chevalier C; Collier A
    Acta Clin Belg; 1990; 45(5):306-10. PubMed ID: 2177299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's Disease Research Group in the United Kingdom.
    BMJ; 1993 Aug; 307(6902):469-72. PubMed ID: 8400928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bromocriptine combined with levodopa in Parkinson's disease.
    Gauthier G; Martins da Silva A
    Eur Neurol; 1982; 21(4):217-26. PubMed ID: 7117308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.